Clinical Trial Update: Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33) [Phase 3]

View source ↗

Summary

Phase 3 study LAS-MD-33 assessed the efficacy and safety of aclidinium bromide in adults with moderate to severe COPD; the study status is completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TUDORZA PRESSAIR (ACLIDINIUM BROMIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-09-13